• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Nameglucose oxidase, glucose
Generic Nameinstrument, glucose, noninvasive technology\
Regulation Number862.1345
ApplicantCYGNUS, INC.
PMA NumberP990026
Supplement NumberS008
Date Received09/19/2001
Decision Date08/26/2002
Product Code
CGA[ Registered Establishments with CGA ]
Docket Number 02M-0412
Notice Date 09/16/2002
Advisory Committee Clinical Chemistry
Supplement Typepanel track
Supplement Reason labeling change - indications
Expedited Review Granted? Yes
Combination Product No
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for the glucowatch g2 biographer, which expands the indications for use to include children/adolescents (age 7 to 17) to the currently approved indications for use. This device is now indicated for the following: 1) the gluco watch g2 biographer is a glucose monitoring device indicated for detecting trends and tracking patterns in glucose levels in adults (age 18 and older) and children/adolescents (age 7 to 17) with diabetes. This device is intended for use by patients at home and in health care facilities. The device is for prescription use only. 2) the glucowatch g2 biographer is indicated for use as an adjunctive device to supplement, not replace, information obtained from standard home glucose monitoring devices. 3) the biographer is indicated for use in the detection and assessment of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments, which may minimized these excursions. Interpretation of biographer results should be based on the trends and patterns seen with several sequential readings over time.
Approval Order Approval Order